Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.
Q4 2025 Management View Jennifer Good, CEO, reported that "2025 was a major inflection point for growth at Trevi, driven by our positive data readouts in both the CORAL trial in patients with ...
United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary ...
Researchers from the US identified transcriptomic differences related to sex in patients with idiopathic pulmonary fibrosis.
Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company’s clinical priorities and upcoming catalysts during ...
Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...
Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. This article is more than 6 years old. Idiopathic pulmonary ...
The MarketWatch News Department was not involved in the creation of this content. CHICAGO, Dec. 22, 2025 /PRNewswire/ -- The Prognostic Lung Fibrosis Consortium (PROLIFIC), a collaborative consortium ...
The actor tells AARP about her mom’s struggle with pulmonary fibrosis and the warning signs that might help others get an earlier diagnosis ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...